Drugs / Rhenium Liposome Treatment
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01906385 | Jun 2015 → Dec 2025 overdue | glioma | Plus Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2025-12-04 | Plus Therapeutics | Results Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting cerenome.com ↗
Phase 1 ReSPECT-GBM showed promising improvements in overall survival |
| 2025-08-18 | Plus Therapeutics | Results Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases cerenome.com ↗
The data demonstrated treatment of leptomeningeal metastases (LM) with REYOBIQ is feasible, has a manageable safety profile, and shows a promising efficacy signal. |
| 2023-06-29 | Plus Therapeutics | Results Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting cerenome.com ↗
A single dose of rhenium ( 186 Re) obisbemeda was generally safe and well-tolerated, with no dose-limiting toxicities and minimal systemic radiation exposure. |
| 2022-09-12 | Plus Therapeutics | Results Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022 cerenome.com ↗
In the ReSPECT-GBM Phase 1 trial, we achieved up to 20 times the amount of radiation compared to external beam radiation therapy, and we observed a statistically significant improvement in survival in those patients receiving a therapeutic dose of radiation compared to those that did not. |
| 2022-08-13 | Plus Therapeutics | Results Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases cerenome.com ↗
Furthermore, all three patients in the cohort were observed to have prompt and complete 186 RNL distribution throughout the cerebrospinal fluid (CSF) subarachnoid space that was durable past one week and very well tolerated. |
| 2021-11-09 | Plus Therapeutics | Regulatory Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases cerenome.com ↗ |
All press releases naming this drug 9 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rhenium Liposome Treatment | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01906385 ↗ |
| Known as | 186RNL | “A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)” NCT01906385 ↗ |
| Modality | Other / unclassified | “radiolabeled liposomes” PMID 39032243 ↗ Jul 2024 |
| Route | Other | “186RNL will be infused through the CED catheter” NCT01906385 ↗ |